Pharmaids Pharmaceuticals Limited has informed the stock exchanges that its board of directors will meet on Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will review both standalone and consolidated financial statements during the session.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s code of conduct, the trading window for dealing in the securities of the company has been closed. This restriction applies to designated persons and their immediate relatives. The window will remain shut until 48 hours after the declaration of the audited financial results to the stock exchange.

Meeting Details

The company stated that this information is also available on its official website. The intimation was signed by Prasanna Subramanya Bhat, Company Secretary & Compliance Officer.

Pharmaids Pharmaceuticals Limited has announced the opening of a special window for re-lodgement of physical share transfer requests, providing shareholders with an opportunity to complete previously unsuccessful transactions. The company disclosed this development through a newspaper publication in Financial Express on Friday, April 24, 2026.

Regulatory Compliance and Timeline

The special window initiative follows SEBI circular no. HO/38/13/11(2)2026–MIRSD–POD/I/3750/2026 dated January 30, 2026, and will remain operational for one year from February 05, 2026 to February 04, 2027. This regulatory framework addresses the need to process physical share transfers that were submitted prior to April 01, 2019 but remained unprocessed due to various deficiencies.

Transfer Process and Requirements

As mandated by SEBI regulations, all approved transfers will be executed exclusively in dematerialised form and will be subject to a lock-in period of one year from the date of registration. Eligible shareholders are required to rectify previously identified deficiencies before re-submitting their transfer requests.

The company has designated M/s. Venture Capital And Corporate Investments Private Limited as the Registrar and Share Transfer Agent for processing these requests. The registrar is located at Unit: "Aurum", door no. 4-50/P-II/57/4F & 5F, 4th & 5th Floor, Plot No. 57, Jayabheri Enclave Phase - II, Gachibowli, Hyderabad - 500 032.

Eligible Cases and Documentation

The special window specifically targets physical securities that were submitted prior to April 01, 2019 and were subsequently rejected, returned, or remained unattended due to:

• Deficiency in documents
• Process-related issues
• Other administrative concerns

Shareholders must ensure all previously identified deficiencies are addressed before re-lodging their cases with the registrar during the specified window period.

Corporate Disclosure Details

Prasanna Subramanya Bhat, Company Secretary & Compliance Officer, signed the disclosure on April 24, 2026. The information has been made available on the company's website at www.pharmaids.com and submitted to BSE Limited under Regulation 30 of the SEBI Listing Regulations.